Tenaya Therapeutics Q3 2026 Results: Net Loss of $18.9M, Loss Narrows
Tenaya Therapeutics reported a significant decrease in total assets from $146.9 million at the end of 2025 to $76.7 million as of September 30, 2026, driven by a reduction in cash and property assets. The company's accumulated deficit increased to $686.6 million, reflecting ongoing research and development losses as it advances its gene therapy pipeline for heart disease.
- Key figure
- Net loss $18.9M